Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with pathologically confirmed colorectal carcinoma that is metastatic or unresectable and which is refractory to standard therapy. To be considered refractory, a subject must have experienced progression (or intolerance) after treatment with standard approved regimens including, oxaliplatin, irinotecan flouropyrimidine, bevacizumab, and cetuximab or panitumumab if KRAS wildtype.~2. Subjects will not be treated with any radiation, chemotherapy, or investigational agents while enrolled in this protocol.~3. Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2.~4. At least 2 weeks since the last previous cancer treatment including: chemotherapy, radiation therapy, immunotherapy, surgery, hormonal therapy, or targeted biologics.~5. Age ≥ 18 years, male or female subjects.~6. Serum potassium and magnesium levels within institutional normal limits. Total serum calcium or ionized calcium level must be greater than or equal to the lower limit of normal.~7. Adequate renal function, defined by serum creatinine ≤ 1.5 x ULN.~8. Adequate hepatic function~9. Adequate bone marrow function~10. For women of childbearing potential (WOCBP), a negative serum pregnancy test result at Screening.~11. Signed and dated institutional review board (IRB)-approved informed consent before any protocol-specific screening procedures are performed.~12. Patients enrolled must, in the Investigator's judgment, be healthy enough to stay on the clinical trial for three months.~Exclusion Criteria:~1. Mechanical obstruction that would prevent adequate oral nutritional intake.~2. Serious uncontrolled medical disorder, or active infection, that would impair the ability of the patient to receive protocol therapy.~3. Uncontrolled or significant cardiovascular disease, including:~4. Dementia or altered mental status that would prohibit the understanding or rendering of informed consent.~5. Subjects who have not recovered from the adverse effects of prior therapy at the time of enrollment to ≤ grade 1; excluding alopecia and grade 2 neuropathy.~6. Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).~7. Known hepatitis B surface antigen and/or positive hepatitis C antibody and presence of hepatitis C RNA.~8. History of tuberculosis (latent or active) or positive Interferon-gamma release assay (IGRA).~9. Receipt of a live (attenuated) vaccine within 1 month prior to Screening~10. Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition of XILONIX™.~11. Women who are pregnant or breastfeeding.~12. WOCBP or men whose sexual partners are WOCBP who are unwilling or unable to use an acceptable method of contraception for at least 1 month prior to study entry, for the duration of the study, and for at least 3 months after the last dose of study medication.~13. Weight loss \>20% in the previous 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xilonix (Type: EXPERIMENTAL): MABp1 administered IV every two weeks, plus best supportive care
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered IV every two weeks, plus best supportive care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy